Shares of Suven Life Sciences jumped 8.87% on Tuesday after the company announced its clinical research division Asian Clinical Trials (ACT) has entered into a strategic alliance with VPSCRO, a CRO based in Beijing, China to conduct clinical trial services in India, as well as in China.
Shares of the company surged Rs 2.70, or 8.87%, to trade at Rs 33.15. The stock has shown a rise of 0.76% over the week and fall of 2.93% over a month. The total volume of shares traded was 59,255 at the BSE. (3.07 p.m., Tuesday)
This strategic alliance between ACT and VPSCRO will allow the company to offer compressive range of clinical services to global sponsors with the state of the art infrastructure, network of trained investigators in India and China by leveraging their expertise for the conduct of quality clinical research.
``We are very enthusiastic with the many opportunities to make this alliance a success not only for ACT and VPSCRO, but also to our global sponsors around the world``, says Venkat Jasti, CEO of Suven Life Sciences.